[144] Sionna Therapeutics, Inc. SEC Filing
Sionna Therapeutics filed a Form 144 reporting a proposed sale of common stock. The notice shows 54,637 shares to be sold through Merrill Lynch on NASDAQ, with an aggregate market value of $1,581,194.78 and approximately 44,139,823 shares outstanding. The shares were acquired in a private placement from the issuer on 03/04/2024 and paid in cash on that date. The filing states there were no securities sold by the reporting person in the past three months. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information.
Sionna Therapeutics ha presentato un modulo 144 che segnala la vendita proposta di azioni ordinarie. La nota mostra 54.637 azioni da vendere tramite Merrill Lynch su NASDAQ, con un valore di mercato complessivo di 1.581.194,78 dollari e circa 44.139.823 azioni ordinarie in circolazione. Le azioni sono state acquisite in un collocamento privato dall'emittente il 04/03/2024 e pagate in contanti in quella data. La dichiarazione indica che negli ultimi tre mesi la persona che segnala non ha venduto titoli. L'avviso contiene la dichiarazione standard secondo cui il venditore non è a conoscenza di alcuna informazione dannosa non divulgata.
Sionna Therapeutics presentó un Formulario 144 reportando la venta propuesta de acciones comunes. El aviso muestra 54.637 acciones a vender a través de Merrill Lynch en NASDAQ, con un valor de mercado agregado de 1.581.194,78 USD y aproximadamente 44.139.823 acciones en circulación. Las acciones se adquirieron en una colocación privada del emisor el 04/03/2024 y se pagaron en efectivo en esa fecha. La presentación indica que no se han vendido valores por la persona reportante en los últimos tres meses. El aviso incluye la declaración estándar de que el vendedor no está al tanto de ninguna información material adversa no revelada.
시온나 테라퓨틱스는 보통주 매각을 보고하는 Form 144를 제출했습니다. 통지는 매도될 54,637주를 Merrill Lynch를 통해 NASDAQ에서 판매하며, 총 시가가 1,581,194.78달러이고 발행주식 총수는 약 44,139,823주입니다. 해당 주식은 2024년 3월 4일 발행기업의 비공개 배정으로 취득했고 그 날 현금으로 지급되었습니다. 신고자인 최근 3개월 동안 매도된 증권은 없다고 기재되어 있습니다. 통지에는 매도인이 비공개로 공개되지 않은 중요한 악재 정보가 없다는 표준 진술이 포함돼 있습니다.
Sionna Therapeutics a déposé un formulaire 144 signalant la vente proposée d'actions ordinaires. L'avis indique 54 637 actions à vendre par l'intermédiaire de Merrill Lynch sur le NASDAQ, pour une valeur de marché totale de 1 581 194,78 dollars et environ 44 139 823 actions en circulation. Les actions ont été acquises lors d'un placement privé de l'émetteur le 04/03/2024 et ont été payées en espèces à cette date. Le dossier indique qu'aucune valeur mobilière n'a été vendue par la personne déclarante au cours des trois derniers mois. L'avis inclut la déclaration standard selon laquelle le vendeur n'est pas au courant d'aucune information défavorable matérielle non divulguée.
Sionna Therapeutics hat ein Formular 144 eingereicht, das den beabsichtigten Verkauf von Stammaktien meldet. Der Hinweis zeigt 54.637 Aktien, die über Merrill Lynch an der NASDAQ verkauft werden sollen, mit einem Gesamtmarktwert von 1.581.194,78 USD und etwa 44.139.823 ausstehenden Aktien. Die Aktien wurden in einer privaten Platzierung des Emittenten am 04.03.2024 erworben und an diesem Datum bar bezahlt. Die Einreichung gibt an, dass in den letzten drei Monaten durch die meldende Person keine Wertpapiere verkauft wurden. Der Hinweis enthält die Standardaussage, dass der Verkäufer über keine nicht offengelegten wesentlichen nachteiligen Informationen verfügt.
قدمت سيو نا ثيرابيوتكس نموذج 144 للإبلاغ عن بيع مقترح للأسهم العادية. يُظهر الإشعار 54,637 سهماً ليباع من خلال ميريل لنش في ناسداك، بقيمة سوقية إجمالية قدرها 1,581,194.78 دولاراً وما يقرب من 44,139,823 سهماً قائماً. تمت محproc الملك الأسهم من خلال تخصيص خاص من الجهة المصدرة في 04/03/2024 ودُفعت قيمتها نقداً في ذلك التاريخ. التنصيق يشير إلى أنه لم يتم بيع أي أوراق مالية من قبل الشخص المبلغ خلال الأشهر الثلاثة الماضية. الإشعار يتضمن البيان القياسي بأن البائع غير على علم بأي معلومات سلبية جوهرية لم تُكشف.
Sionna Therapeutics 已提交 Form 144，报告拟议出售普通股。 该通知显示通过 Merrill Lynch 在 NASDAQ 上待售的 54,637 股，市场总值为 1,581,194.78 美元，外加约 44,139,823 股已发行在外。 这些股票于 2024 年 3 月 4 日通过发行方的私募配售取得，且在当天以现金支付。备案表示，在过去的三个月内，报告人没有出售任何证券。通知包含标准声明，即卖方并不知晓任何未披露的重大不利信息。
- Acquisition and payment were completed in cash on 03/04/2024, indicating clear title to the shares
- No securities sold in the prior three months by the reporting person, simplifying interpretation of trading activity
- Proposed sale of 54,637 shares (aggregate market value $1,581,194.78) is scheduled, which may indicate insider liquidity
- Sale set for 09/29/2025, creating a future supply event that could modestly increase sell-side pressure on the stock that day
Insights
TL;DR: Insider/affiliate plans a modest sale of 54,637 common shares valued at $1.58M; transaction originated from a private placement.
The Form 144 discloses a proposed sale executed through Merrill Lynch on NASDAQ, listing the security class, quantity, and aggregate value. The shares were acquired via a private placement from the issuer on 03/04/2024 and fully paid in cash that same day. There are no reported sales by the filer in the prior three months, which limits near-term disposition history. Relative to the ~44.14 million shares outstanding, the amount represents a small fraction of the float, suggesting limited direct dilution or market impact. The filing contains the routine attestation regarding undisclosed material adverse information.
TL;DR: Routine disclosure of a planned sale by a person who acquired shares in a private placement; governance signal is neutral.
The notice follows Rule 144 requirements by identifying the broker, proposed sale date (09/29/2025), and acquisition details. Because the acquisition was from the issuer via private placement, the filing clarifies the holding origin and payment method. The absence of other recent sales reduces complexity in assessing trading pattern. The standard seller representation about material information is present. Overall, this is a compliance-focused filing rather than an event that by itself implies a corporate governance change.
Sionna Therapeutics ha presentato un modulo 144 che segnala la vendita proposta di azioni ordinarie. La nota mostra 54.637 azioni da vendere tramite Merrill Lynch su NASDAQ, con un valore di mercato complessivo di 1.581.194,78 dollari e circa 44.139.823 azioni ordinarie in circolazione. Le azioni sono state acquisite in un collocamento privato dall'emittente il 04/03/2024 e pagate in contanti in quella data. La dichiarazione indica che negli ultimi tre mesi la persona che segnala non ha venduto titoli. L'avviso contiene la dichiarazione standard secondo cui il venditore non è a conoscenza di alcuna informazione dannosa non divulgata.
Sionna Therapeutics presentó un Formulario 144 reportando la venta propuesta de acciones comunes. El aviso muestra 54.637 acciones a vender a través de Merrill Lynch en NASDAQ, con un valor de mercado agregado de 1.581.194,78 USD y aproximadamente 44.139.823 acciones en circulación. Las acciones se adquirieron en una colocación privada del emisor el 04/03/2024 y se pagaron en efectivo en esa fecha. La presentación indica que no se han vendido valores por la persona reportante en los últimos tres meses. El aviso incluye la declaración estándar de que el vendedor no está al tanto de ninguna información material adversa no revelada.
시온나 테라퓨틱스는 보통주 매각을 보고하는 Form 144를 제출했습니다. 통지는 매도될 54,637주를 Merrill Lynch를 통해 NASDAQ에서 판매하며, 총 시가가 1,581,194.78달러이고 발행주식 총수는 약 44,139,823주입니다. 해당 주식은 2024년 3월 4일 발행기업의 비공개 배정으로 취득했고 그 날 현금으로 지급되었습니다. 신고자인 최근 3개월 동안 매도된 증권은 없다고 기재되어 있습니다. 통지에는 매도인이 비공개로 공개되지 않은 중요한 악재 정보가 없다는 표준 진술이 포함돼 있습니다.
Sionna Therapeutics a déposé un formulaire 144 signalant la vente proposée d'actions ordinaires. L'avis indique 54 637 actions à vendre par l'intermédiaire de Merrill Lynch sur le NASDAQ, pour une valeur de marché totale de 1 581 194,78 dollars et environ 44 139 823 actions en circulation. Les actions ont été acquises lors d'un placement privé de l'émetteur le 04/03/2024 et ont été payées en espèces à cette date. Le dossier indique qu'aucune valeur mobilière n'a été vendue par la personne déclarante au cours des trois derniers mois. L'avis inclut la déclaration standard selon laquelle le vendeur n'est pas au courant d'aucune information défavorable matérielle non divulguée.
Sionna Therapeutics hat ein Formular 144 eingereicht, das den beabsichtigten Verkauf von Stammaktien meldet. Der Hinweis zeigt 54.637 Aktien, die über Merrill Lynch an der NASDAQ verkauft werden sollen, mit einem Gesamtmarktwert von 1.581.194,78 USD und etwa 44.139.823 ausstehenden Aktien. Die Aktien wurden in einer privaten Platzierung des Emittenten am 04.03.2024 erworben und an diesem Datum bar bezahlt. Die Einreichung gibt an, dass in den letzten drei Monaten durch die meldende Person keine Wertpapiere verkauft wurden. Der Hinweis enthält die Standardaussage, dass der Verkäufer über keine nicht offengelegten wesentlichen nachteiligen Informationen verfügt.
FAQ
What does SION Form 144 report?
When were the shares acquired that are being sold under the Form 144?
Who is the broker handling the proposed sale in the SION Form 144?
What is the approximate share count outstanding used in the filing?
Are there any other sales by the filer in the past three months?
